This company has been marked as potentially delisted and may not be actively trading. Bioblast Pharma (ORPN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock ORPN vs. GRTX, ADXS, VCNX, ASLN, EVFM, PTPI, BPTH, ATHX, PBLA, and HEPAShould you be buying Bioblast Pharma stock or one of its competitors? The main competitors of Bioblast Pharma include Galera Therapeutics (GRTX), Ayala Pharmaceuticals (ADXS), Vaccinex (VCNX), ASLAN Pharmaceuticals (ASLN), Evofem Biosciences (EVFM), Petros Pharmaceuticals (PTPI), Bio-Path (BPTH), Athersys (ATHX), Panbela Therapeutics (PBLA), and Hepion Pharmaceuticals (HEPA). These companies are all part of the "medical" sector. Bioblast Pharma vs. Its Competitors Galera Therapeutics Ayala Pharmaceuticals Vaccinex ASLAN Pharmaceuticals Evofem Biosciences Petros Pharmaceuticals Bio-Path Athersys Panbela Therapeutics Hepion Pharmaceuticals Bioblast Pharma (NASDAQ:ORPN) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation. Which has more volatility & risk, ORPN or GRTX? Bioblast Pharma has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Which has stronger earnings and valuation, ORPN or GRTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioblast PharmaN/AN/A-$5.94MN/AN/AGalera TherapeuticsN/AN/A-$59.08M-$0.19-0.09 Do institutionals and insiders hold more shares of ORPN or GRTX? 4.5% of Bioblast Pharma shares are held by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer ORPN or GRTX? In the previous week, Bioblast Pharma's average media sentiment score of 0.00 equaled Galera Therapeutics'average media sentiment score. Company Overall Sentiment Bioblast Pharma Neutral Galera Therapeutics Neutral Is ORPN or GRTX more profitable? Company Net Margins Return on Equity Return on Assets Bioblast PharmaN/A N/A N/A Galera Therapeutics N/A N/A -99.34% SummaryGalera Therapeutics beats Bioblast Pharma on 3 of the 5 factors compared between the two stocks. Get Bioblast Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ORPN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart ORPN vs. The Competition Export to ExcelMetricBioblast PharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$445K$952.75M$5.83B$9.92BDividend YieldN/A4.84%6.70%4.52%P/E RatioN/A1.1476.1526.13Price / SalesN/A26.54553.26185.03Price / CashN/A19.5636.9959.28Price / Book0.146.7311.486.09Net Income-$5.94M-$3.82M$3.29B$266.51M Bioblast Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORPNBioblast PharmaN/A$1.06-0.9%N/A-13.8%$445KN/A0.00N/AHigh Trading VolumeGRTXGalera TherapeuticsN/A$0.02-7.4%N/A-77.3%$1.51MN/A-0.0630Gap DownHigh Trading VolumeADXSAyala PharmaceuticalsN/A$0.03flatN/A+66.5%$1.42M$3.24M0.0020Gap UpVCNXVaccinex0.4171 of 5 stars$0.50+11.1%N/A-90.6%$1.30M$388K-0.0140Short Interest ↑Gap DownASLNASLAN PharmaceuticalsN/A$0.60flatN/AN/A$1.23M$12M-0.0330EVFMEvofem Biosciences0.7525 of 5 stars$0.01-2.0%N/A+11.1%$1.16M$11.39M-0.02120Short Interest ↑Gap UpPTPIPetros Pharmaceuticals0.7077 of 5 stars$0.03+0.3%N/A-99.7%$904K$5.11M-0.0120News CoverageBPTHBio-Path0.4972 of 5 stars$0.11-12.3%N/A-87.8%$898KN/A0.0010Short Interest ↑Gap UpATHXAthersysN/AN/AN/AN/A$833K$146K0.0024PBLAPanbela Therapeutics0.0817 of 5 stars$0.16flatN/AN/A$767KN/A0.006Gap DownHEPAHepion Pharmaceuticals0.295 of 5 stars$0.07-17.1%N/A-99.8%$763KN/A-0.0220Negative NewsShort Interest ↑Gap Up Related Companies and Tools Related Companies Galera Therapeutics Competitors Ayala Pharmaceuticals Competitors Vaccinex Competitors ASLAN Pharmaceuticals Competitors Evofem Biosciences Competitors Petros Pharmaceuticals Competitors Bio-Path Competitors Athersys Competitors Panbela Therapeutics Competitors Hepion Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORPN) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioblast Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioblast Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORPN Stock Alerts